Permeability (electromagnetism)

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Retrieved on: 
Friday, December 8, 2023
Hepatic encephalopathy, Ipsen, AASLD, Cell death, Food, Itch, Priority review, Food and Drug Administration, PSC, IND, ACLF, Marketing, FDA, EMA, MAA, PDUFA, Permeability (electromagnetism), Liver, NDA, Inflammation, Primary sclerosing cholangitis, ALP, Capital market, Hyperammonemia, Patient, NTZ, Fibrosis, PBC, ASK1

Launches in the US and Europe will also make GENFIT eligible for royalty payments.

Key Points: 
  • Launches in the US and Europe will also make GENFIT eligible for royalty payments.
  • Revenues will fund the development of GENFIT’s pipeline, now mainly focused on Acute On-Chronic Liver Failure (ACLF) with 5 differentiated assets.
  • Acceptance of filings in the US and Europe have triggered the first milestone payment for GENFIT.
  • Ipsen also indicated that it is developing elafibranor in Primary Sclerosing Cholangitis (PSC) which could lead to further revenues for GENFIT under the licensing agreement.

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
Thursday, November 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

Vesselon Introduces the First On-site Co-formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs

Retrieved on: 
Monday, August 28, 2023
Liposome, Tissue, Drug, CMC, Permeability (electromagnetism), Endocytosis, Research, Cell, PGP, Dicarboxylic acid, Patent, NCE, Cell death, Apoptosis, Neoplasm, FDA, Virus, Microparticle, Safety, Fine chemical, Pharmaceutical industry, Medical device, Vaccine

GREENWICH, Conn., Aug. 28, 2023 /PRNewswire/ -- Vesselon Inc. introduced the first on-site co-formulation platform that can enhance cellular uptake and response to therapy, without altering the active drug in any way. Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.

Key Points: 
  • Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.
  • Without changing pharmaceutical manufacturing, CMC, or distribution practices, the platform can protect and differentiate an endless stream of blockbuster drugs.
  • "We encapsulate many different classes of drugs, from small molecules, monoclonal antibodies, nucleic acids to viruses," said Clay Larsen, CEO of Vesselon.
  • "I think the best way to think about our approach is that it changes the ability of tissues to receive and act on the drug.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland, July 10, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland  , July 9, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan

Retrieved on: 
Friday, February 11, 2022
Inflammatory bowel disease, NASDAQ, Intellectual property, Patient, HSD, Food, CEO, IBD, Immunosuppression, Ulcerative colitis, FXR, Company, Permeability (electromagnetism), SEC, U.S. Securities and Exchange Commission, SAN, Security (finance), Private Securities Litigation Reform Act, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Institute of Liver and Biliary Sciences, MHS, FDA, MTCR, Investment, GLOBE, Pharmaceutical industry, Risk management

To support ongoing clinical development of MET642 in IBD, the Company is implementing a restructuring plan to significantly reduce expenses associated with its operations in order to preserve cash.

Key Points: 
  • To support ongoing clinical development of MET642 in IBD, the Company is implementing a restructuring plan to significantly reduce expenses associated with its operations in order to preserve cash.
  • As a result, Metacrine has also discontinued preclinical development of its hydroxysteroid dehydrogenase (HSD) program.
  • We are now focusing all of our development effort on bringing expanded therapeutic options to people living with IBD, said Preston Klassen, M.D., MHS, CEO, Metacrine.
  • We have generated preclinical data that supports moving our MET642 program into clinical testing in IBD during the next few months.

DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

Retrieved on: 
Wednesday, January 5, 2022
OHSU, COVID-19, Severe acute respiratory syndrome coronavirus 2, Critical care, Wake Forest School of Medicine, BVA, Doctor of Philosophy, Research, Patient, NYSE, NYSE MKT, Shock, NYU Langone Health, COVID, MD, Data analysis, Health, Plasma, RCT, Mortality, Heart failure, GLOBE, Technology, Permeability (electromagnetism), Pharmaceutical industry, Medicine

Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic.

Key Points: 
  • The study, titled Blood volume and albumin transudation in critically-ill COVID-19 patients, showed that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of only through the use of the Daxor BVA-100 blood test.
  • Jonathan Feldschuh, Chief Scientific Officer of Daxor, stated, Accurate volume assessment allows for individualized care, ensuring circulatory integrity and optimal tissue perfusion.
  • We believe the study results will further validate and broaden the need for blood volume analysis to optimize treatment and improve outcomes for patients.
  • Daxor is the global leader in blood volume measurement technology, utilized by major healthcare systems in the United States.

Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs

Retrieved on: 
Thursday, October 21, 2021
Safety, MHS, Immunosuppression, IBD, Conditional sentence, Permeability (electromagnetism), FXR, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, SEC, Review, Â, Toxicology, Company, Clinical trial, Trial of the century, CEO, Program, NASH, Degenerative disease, Klassen, Liver, Pharmaceutical industry

In this small interim analysis, the 6 mg cohort displayed a non-normal distribution in liver fat changes, as evidenced by differences between the mean and median results.

Key Points: 
  • In this small interim analysis, the 6 mg cohort displayed a non-normal distribution in liver fat changes, as evidenced by differences between the mean and median results.
  • NASH is a complex and chronic disease that we believe will likely require combination regimes to most effectively treat patients.
  • FXR therapy could potentially change the IBD treatment paradigm by bringing an oral, once-daily, well-tolerated and non-immunosuppressive medicine to patients.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.